Component: (Network and Table)
Network
00500 - Statement - Statements of Cash Flows
(http://www.loxooncology.com/role/StatementStatementsOfCashFlows)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0001581720 (http://www.sec.gov/CIK)
Statements of Cash FlowsPeriod [Axis]
2016-01-01 - 2016-12-31
2015-01-01 - 2015-12-31
2014-01-01 - 2014-12-31
Statements of Cash Flows
 
 
 
Operating activities:
 
 
 
Net loss
(72,398,000) 
(35,876,000) 
(20,672,000) 
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
Amortization of premium and discounts on investments
528,000  
391,000  
29,000  
Depreciation of property and equipment
77,000  
17,000  
1,000  
Stock-based compensation
7,960,000  
6,154,000  
3,049,000  
Changes in operating assets and liabilities:
 
 
 
Prepaid expenses and other assets
224,000  
(1,971,000) 
(1,256,000) 
Accounts payable
792,000  
30,000  
18,000  
Accrued expenses and other current liabilities
11,499,000  
1,073,000  
1,136,000  
Net cash used in operating activities
(51,318,000) 
 
(30,182,000) 
 
(17,695,000) 
 
Investing activities:
 
 
 
Purchases of available-for-sale securities
(163,290,000) 
(133,730,000) 
(74,566,000) 
Proceeds from maturing available-for-sale securities
137,038,000  
116,646,000  
5,500,000  
Purchase of property and equipment
(237,000) 
(93,000) 
(14,000) 
Net cash used in investing activities
(26,489,000) 
 
(17,177,000) 
 
(69,080,000) 
 
Financing activities:
 
 
 
Proceeds from issuance of redeemable convertible preferred stock, net
  
43,178,000  
Proceeds from issuance of common stock, net
38,733,000  
71,299,000  
74,164,000  
Proceeds from the exercise of stock options
1,273,000  
307,000  
167,000  
Payment of deferred financing fees
  
(1,798,000) 
Net cash provided by financing activities
40,006,000  
 
71,606,000  
 
115,711,000  
 
Net (decrease) increase in cash and cash equivalents
(37,801,000) 
 
24,247,000  
 
28,936,000  
 
Cash and cash equivalents-beginning of year
68,177,000  
43,930,000  
14,994,000  
Cash and cash equivalents-end of year
30,376,000  
 
68,177,000  
 
43,930,000  
 
Supplemental schedule of noncash financing activities:
 
 
 
Conversion of redeemable convertible preferred stock into common stock
  
68,055,000  
Reclassification of share repurchase obligation
 
37,000